NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $35.35 +0.98 (+2.85%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$35.35 +0.00 (+0.00%) As of 07/2/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Agios Pharmaceuticals Stock (NASDAQ:AGIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Agios Pharmaceuticals alerts:Sign Up Key Stats Today's Range$34.03▼$35.8550-Day Range$27.32▼$35.7552-Week Range$23.42▼$62.58Volume606,160 shsAverage Volume651,976 shsMarket Capitalization$2.05 billionP/E Ratio3.15Dividend YieldN/APrice Target$58.60Consensus RatingModerate Buy Company Overview Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Read More Agios Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreAGIO MarketRank™: Agios Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 217th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is 3.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is 3.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.19.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.79% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Agios Pharmaceuticals has recently increased by 1.65%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.06 Percentage of Shares Shorted7.79% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Agios Pharmaceuticals has recently increased by 1.65%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.23 News SentimentAgios Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Agios Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,165,424.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Stock News HeadlinesAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones Sells 1,780 SharesJune 27, 2025 | insidertrades.comBrokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $58.60July 2 at 2:15 AM | americanbankingnews.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. | Porter & Company (Ad)AGIO | Agios Pharmaceuticals Inc. Annual Cash Flow Statement - MarketWatchJuly 1 at 9:52 AM | marketwatch.comAgios pharma chief legal officer Burns sells $93k in stockJune 28, 2025 | investing.comAGIO Agios Pharmaceuticals, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comAGIO - Agios Pharmaceuticals Inc Chart - MorningstarJune 26, 2025 | morningstar.comMAgios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market PotentialJune 17, 2025 | msn.comSee More Headlines AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $32.86 on January 1st, 2025. Since then, AGIO stock has increased by 7.6% and is now trading at $35.35. View the best growth stocks for 2025 here. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The biopharmaceutical company earned $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 2.75% and a net margin of 1,798.26%. Read the conference call transcript. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/01/2025Today7/02/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGIO CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/APrice Target and Rating Average Stock Price Target$58.60 High Stock Price Target$71.00 Low Stock Price Target$51.00 Potential Upside/Downside+65.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$11.24 Trailing P/E Ratio3.15 Forward P/E RatioN/A P/E GrowthN/ANet Income$673.72 million Net Margins1,798.26% Pretax Margin1,917.72% Return on Equity-2.75% Return on Assets-2.52% Debt Debt-to-Equity RatioN/A Current Ratio18.50 Quick Ratio17.93 Sales & Book Value Annual Sales$36.50 million Price / Sales56.10 Cash FlowN/A Price / Cash FlowN/A Book Value$27.02 per share Price / Book1.31Miscellaneous Outstanding Shares57,920,000Free Float55,425,000Market Cap$2.05 billion OptionableOptionable Beta0.73 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AGIO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.